The October 2026 news for men is wider over-the-counter access plus longer follow-up for an investigational oral drug, with no new acne-specific FDA approval in September. Epiduo Gel, a fixed-dose combination gel with adapalene 0.1% plus benzoyl peroxide 2.5%, moved from prescription to over-the-counter, while oral denifanstat showed sustained lesion reductions through 52 weeks. That matters for men because androgen stimulation drives sebum and breakouts. Testosterone therapy and male-pattern hormone shifts raise that risk even when dosing stays in the intended range.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Hcplive — Use this primary source to verify the official announcement.
- Read the original report from Mdedge — Use this primary source to review the complete report.
Table of Contents
- Can men get Epiduo without a prescription?
- How strong is the denifanstat 52-week data?
- Why does testosterone drive male breakouts?
- What should men do differently now?
Can men get Epiduo without a prescription?
Yes. Galderma said in a Business Wire announcement that FDA approved the prescription-to-OTC switch for ages 12 and older, with retail availability announcement planned for summer 2026 at Walmart, Ulta and Target. That gives men prescription-strength access without a clinic visit.
The practical point is combination treatment. MDedge reporting on current AAD guidance notes strong support for benzoyl peroxide, retinoids, fixed-dose combinations, and oral isotretinoin for severe disease. Men using Epiduo cover two of those pillars at once.
How strong is the denifanstat 52-week data?
Dermatology Times reported about 57% Investigator's Global Assessment success, with 72% mean total-lesion and 77% inflammatory-lesion reductions through up to 52 weeks in moderate-to-severe acne in Phase 3 open-label extension ASC40-304 in its 52-week results summary. The extension followed longer treatment, not a short course. Denifanstat remains investigational for acne and is not FDA-approved, according to a Sagimet press release carried by Stockhouse with the full 52-week press release.
That release says the 52-week data came from license partner Ascletis' China extension of 240 patients, while U.S. Phase 3 AURORA screening was imminent. HCPlive's September 2026 recap also highlighted no new acne-specific FDA approval that month.
Why does testosterone drive male breakouts?
A 2026 JAMA Dermatology cohort study reported via Healio found acne developed more often after starting any gender-affirming hormone therapy than in matched cisgender controls. Risk was highest in the first year for transmasculine patients on testosterone.
Medscape reporting on that study quantified the first-year testosterone signal as hazard ratio 8.29 versus matched cisgender males and 2.63 versus matched cisgender females. That supports androgen-driven sebum as the key mechanism in male acne. NovaGenix, updated in September 2026, adds that testosterone replacement therapy can cause or worsen acne by increasing oil-gland stimulation even within the intended range.
What should men do differently now?
Use the OTC option as directed and avoid antibiotic monotherapy. Current AAD guidance described by MDedge strongly recommends topical benzoyl peroxide, retinoids and/or antibiotics plus fixed-dose combinations, with oral isotretinoin for severe disease, and advises combining therapies in its AAD guidance update.
Watch hormone-linked warning signs closely: NovaGenix advises early medical review for painful, scarring, or persistent breakouts without automatically stopping TRT. Bring a full medication list, including TRT dose and start date, to that visit.
- new jawline, chest, or back breakouts within months of starting TRT
- painful nodules, scarring, or breakouts that persist past 6 to 8 weeks
- sudden worsening after a dose change
You Might Also Like
- What Is New With Retinoids and Acne in October 2026? Latest FDA and dermatology sources and Key Takeaways
- What Is New With Cleansers and Acne in October 2026? Latest FDA and dermatology sources and Key Takeaways
- How to Verify Treatments and Acne Claims in 2026: FDA and dermatology sources, Evidence, and Red Flags